205 related articles for article (PubMed ID: 1830248)
1. Combination of etanidazole with cyclophosphamide and platinum complexes.
Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
[TBL] [Abstract][Full Text] [Related]
2. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
3. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
[TBL] [Abstract][Full Text] [Related]
4. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
[TBL] [Abstract][Full Text] [Related]
5. Schedule dependent tumour growth delay, DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia or radiation.
Teicher BA; Pfeffer MR; Alvarez Sotomayor E; Herman TS
Int J Hyperthermia; 1991; 7(5):773-84. PubMed ID: 1834752
[TBL] [Abstract][Full Text] [Related]
6. Addition of 2-nitroimidazole radiosensitizers to cis-diamminedichloroplatinum(II) with radiation and with or without hyperthermia in the murine FSaIIC fibrosarcoma.
Herman TS; Teicher BA; Holden SA; Pfeffer MR; Jones SM
Cancer Res; 1990 May; 50(9):2734-40. PubMed ID: 2139359
[TBL] [Abstract][Full Text] [Related]
7. Influence of scheduling on two-drug combinations of alkylating agents in vivo.
Teicher BA; Holden SA; Jones SM; Eder JP; Herman TS
Cancer Chemother Pharmacol; 1989; 25(3):161-6. PubMed ID: 2513139
[TBL] [Abstract][Full Text] [Related]
8. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
[TBL] [Abstract][Full Text] [Related]
10. Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors.
Teicher BA; Chatterjee D; Liu JT; Holden SA; Ara G
Cancer Chemother Pharmacol; 1993; 32(4):315-9. PubMed ID: 8324874
[TBL] [Abstract][Full Text] [Related]
11. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
Teicher BA; Bernal SD; Holden SA; Cathcart KN
Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
[TBL] [Abstract][Full Text] [Related]
12. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E
Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
[TBL] [Abstract][Full Text] [Related]
14. Modulation of alkylating agents by lonidamine in vivo.
Teicher BA; Holden SA; Herman TS; Frei E
Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
[TBL] [Abstract][Full Text] [Related]
15. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
[TBL] [Abstract][Full Text] [Related]
16. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
Teicher BA; Holden SA; Ara G; Ha CS; Herman TS; Northey D
J Cancer Res Clin Oncol; 1992; 118(7):509-14. PubMed ID: 1624542
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.
Brooks SE; Korbut TT; Dupuis NP; Holden SA; Teicher BA
Cancer Chemother Pharmacol; 1995; 36(5):431-8. PubMed ID: 7634385
[TBL] [Abstract][Full Text] [Related]
18. Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.
Teicher BA; Herman TS; Hopkins RE; Menon K
J Cancer Res Clin Oncol; 1992; 118(2):123-8. PubMed ID: 1735732
[TBL] [Abstract][Full Text] [Related]
19. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
Teicher BA; Holden SA; Ara G; Northey D
Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.
Teicher BA; Holden SA; Eder JP; Herman TS; Antman KH; Frei E
Semin Oncol; 1990 Feb; 17(1 Suppl 3):18-32. PubMed ID: 2106164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
